Afuco™ Anti-IL1B ADCC Therapeutic Antibody (Canakinumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to Human IL1 beta. Canakinumab (INN, trade name Ilaris, previously ACZ885) is a human monoclonal antibody targeted at interleukin-1 beta. It has no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha.
Canakinumab was for the treatment of rheumatoid arthritis. Canakinumab is as a possible treatment for chronic obstructive pulmonary disease, gout and coronary artery disease.
Canakinumab was for the treatment of rheumatoid arthritis. Canakinumab is as a possible treatment for chronic obstructive pulmonary disease, gout and coronary artery disease.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-021 |
| Pricing | Inquiry |
| Host | Human |
| Target | IL1B |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | ELISA, IP, FC, FuncS, Neut |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |